Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
316 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Summary Global Markets Direct's, Osteoarthritis - Pipeline Review, H2 2015', provides an overview of the Osteoarthritis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Osteoarthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Osteoarthritis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope The report provides a snapshot of the global therapeutic landscape of Osteoarthritis The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Osteoarthritis and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects A review of the Osteoarthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Osteoarthritis pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Osteoarthritis Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Osteoarthritis pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Introduction 6 Osteoarthritis Overview 7 Therapeutics Development 8 Osteoarthritis - Therapeutics under Development by Companies 10 Osteoarthritis - Therapeutics under Investigation by Universities/Institutes 17 Osteoarthritis - Pipeline Products Glance 18 Osteoarthritis - Products under Development by Companies 21 Osteoarthritis - Products under Investigation by Universities/Institutes 28 Osteoarthritis - Companies Involved in Therapeutics Development 29 Osteoarthritis - Therapeutics Assessment 91 Drug Profiles 104 Osteoarthritis - Recent Pipeline Updates 248 Osteoarthritis - Dormant Projects 285 Osteoarthritis - Discontinued Products 293 Osteoarthritis - Product Development Milestones 295 Appendix 302
List of Tables Number of Products under Development for Osteoarthritis, H2 2015 21 Number of Products under Development for Osteoarthritis - Comparative Analysis, H2 2015 22 Number of Products under Development by Companies, H2 2015 24 Number of Products under Development by Companies, H2 2015 (Contd..1) 25 Number of Products under Development by Companies, H2 2015 (Contd..2) 26 Number of Products under Development by Companies, H2 2015 (Contd..3) 27 Number of Products under Development by Companies, H2 2015 (Contd..4) 28 Number of Products under Development by Companies, H2 2015 (Contd..5) 29 Number of Products under Investigation by Universities/Institutes, H2 2015 30 Comparative Analysis by Late Stage Development, H2 2015 31 Comparative Analysis by Clinical Stage Development, H2 2015 32 Comparative Analysis by Early Stage Development, H2 2015 33 Products under Development by Companies, H2 2015 34 Products under Development by Companies, H2 2015 (Contd..1) 35 Products under Development by Companies, H2 2015 (Contd..2) 36 Products under Development by Companies, H2 2015 (Contd..3) 37 Products under Development by Companies, H2 2015 (Contd..4) 38 Products under Development by Companies, H2 2015 (Contd..5) 39 Products under Development by Companies, H2 2015 (Contd..6) 40 Products under Investigation by Universities/Institutes, H2 2015 41 Osteoarthritis - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2015 42 Osteoarthritis - Pipeline by AbbVie Inc., H2 2015 43 Osteoarthritis - Pipeline by Abiogen Pharma S.p.A., H2 2015 44 Osteoarthritis - Pipeline by Addex Therapeutics Ltd, H2 2015 45 Osteoarthritis - Pipeline by Akari Therapeutics, Plc, H2 2015 46 Osteoarthritis - Pipeline by Ampio Pharmaceuticals, Inc., H2 2015 47 Osteoarthritis - Pipeline by Amura Holdings Limited, H2 2015 48 Osteoarthritis - Pipeline by Arcarios BV, H2 2015 49 Osteoarthritis - Pipeline by Asahi Kasei Pharma Corp., H2 2015 50 Osteoarthritis - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2015 51 Osteoarthritis - Pipeline by Astellas Pharma Inc., H2 2015 52 Osteoarthritis - Pipeline by Biopharm GmbH, H2 2015 53 Osteoarthritis - Pipeline by Can-Fite BioPharma Ltd., H2 2015 54 Osteoarthritis - Pipeline by Cara Therapeutics, Inc., H2 2015 55 Osteoarthritis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2015 56 Osteoarthritis - Pipeline by Cellceutix Corporation, H2 2015 57 Osteoarthritis - Pipeline by Cellular Biomedicine Group, Inc., H2 2015 58 Osteoarthritis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 59 Osteoarthritis - Pipeline by Dong-A ST Co., Ltd., H2 2015 60 Osteoarthritis - Pipeline by Eli Lilly and Company, H2 2015 61 Osteoarthritis - Pipeline by Evgen Pharma PLC, H2 2015 62 Osteoarthritis - Pipeline by Galapagos NV, H2 2015 63 Osteoarthritis - Pipeline by Genequine Biotherapeutics GmbH, H2 2015 64 Osteoarthritis - Pipeline by GlaxoSmithKline Plc, H2 2015 65 Osteoarthritis - Pipeline by IMMD Inc., H2 2015 66 Osteoarthritis - Pipeline by IntelliCell BioSciences Inc., H2 2015 67 Osteoarthritis - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2015 68 Osteoarthritis - Pipeline by Jenrin Discovery, Inc., H2 2015 69 Osteoarthritis - Pipeline by K-Stemcell Co., Ltd., H2 2015 70 Osteoarthritis - Pipeline by Levolta Pharmaceuticals, Inc., H2 2015 71 Osteoarthritis - Pipeline by Medivir AB, H2 2015 72 Osteoarthritis - Pipeline by Merck KGaA, H2 2015 73 Osteoarthritis - Pipeline by Mesoblast Limited, H2 2015 74 Osteoarthritis - Pipeline by Mor Research Application Ltd, H2 2015 75 Osteoarthritis - Pipeline by NicOx S.A., H2 2015 76 Osteoarthritis - Pipeline by Nordic Bioscience A/S, H2 2015 77 Osteoarthritis - Pipeline by Novartis AG, H2 2015 78 Osteoarthritis - Pipeline by Ocata Therapeutics, Inc., H2 2015 79 Osteoarthritis - Pipeline by Omeros Corporation, H2 2015 80 Osteoarthritis - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 81 Osteoarthritis - Pipeline by OrthoCyte Corporation, H2 2015 82 Osteoarthritis - Pipeline by Osteologix Holdings Plc, H2 2015 83 Osteoarthritis - Pipeline by Pfizer Inc., H2 2015 84 Osteoarthritis - Pipeline by Pharmalink AB, H2 2015 85 Osteoarthritis - Pipeline by PolyNovo Limited, H2 2015 86 Osteoarthritis - Pipeline by Regeneus Ltd, H2 2015 87 Osteoarthritis - Pipeline by ReqMed Company, Ltd., H2 2015 88 Osteoarthritis - Pipeline by Rottapharm SpA, H2 2015 89 Osteoarthritis - Pipeline by Sanofi, H2 2015 90 Osteoarthritis - Pipeline by Seikagaku Corporation, H2 2015 91 Osteoarthritis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2015 92 Osteoarthritis - Pipeline by STELIS Biopharma Pvt. Ltd., H2 2015 93 Osteoarthritis - Pipeline by Stempeutics Research Private Limited, H2 2015 94 Osteoarthritis - Pipeline by Symic Biomedical, Inc., H2 2015 95 Osteoarthritis - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 96 Osteoarthritis - Pipeline by TissueGene, Inc., H2 2015 97 Osteoarthritis - Pipeline by Upsher-Smith Laboratories, Inc., H2 2015 98 Osteoarthritis - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H2 2015 99 Osteoarthritis - Pipeline by Yuhan Corporation, H2 2015 100 Osteoarthritis - Pipeline by Yungjin Pharm. Co., Ltd., H2 2015 101 Osteoarthritis - Pipeline by Zimmer Biomet Holdings, Inc., H2 2015 102 Osteoarthritis - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2015 103 Assessment by Monotherapy Products, H2 2015 104 Assessment by Combination Products, H2 2015 105 Number of Products by Stage and Target, H2 2015 107 Number of Products by Stage and Mechanism of Action, H2 2015 111 Number of Products by Stage and Route of Administration, H2 2015 114 Number of Products by Stage and Molecule Type, H2 2015 116 Osteoarthritis Therapeutics - Recent Pipeline Updates, H2 2015 261 Osteoarthritis - Dormant Projects, H2 2015 298 Osteoarthritis - Dormant Projects (Contd..1), H2 2015 299 Osteoarthritis - Dormant Projects (Contd..2), H2 2015 300 Osteoarthritis - Dormant Projects (Contd..3), H2 2015 301 Osteoarthritis - Dormant Projects (Contd..4), H2 2015 302 Osteoarthritis - Dormant Projects (Contd..5), H2 2015 303 Osteoarthritis - Dormant Projects (Contd..6), H2 2015 304 Osteoarthritis - Dormant Projects (Contd..7), H2 2015 305 Osteoarthritis - Discontinued Products, H2 2015 306 Osteoarthritis - Discontinued Products (Contd..1), H2 2015 307
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
